316 related articles for article (PubMed ID: 24882271)
21. Novel inhaled combined antibiotic formulations in the treatment of Pseudomonas aeruginosa airways infections in cystic fibrosis.
Antoniu S
Expert Rev Anti Infect Ther; 2015 Jul; 13(7):897-905. PubMed ID: 25921312
[TBL] [Abstract][Full Text] [Related]
22. Comparison of Inhaled Antibiotics for the Treatment of Chronic Pseudomonas aeruginosa Lung Infection in Patients With Cystic Fibrosis: Systematic Literature Review and Network Meta-analysis.
Elborn JS; Vataire AL; Fukushima A; Aballea S; Khemiri A; Moore C; Medic G; Hemels ME
Clin Ther; 2016 Oct; 38(10):2204-2226. PubMed ID: 27692977
[TBL] [Abstract][Full Text] [Related]
23. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
Ramsey BW; Pepe MS; Quan JM; Otto KL; Montgomery AB; Williams-Warren J; Vasiljev-K M; Borowitz D; Bowman CM; Marshall BC; Marshall S; Smith AL
N Engl J Med; 1999 Jan; 340(1):23-30. PubMed ID: 9878641
[TBL] [Abstract][Full Text] [Related]
24. New Inhaled Antimicrobial Formulations for Use in the Cystic Fibrosis Patient Population.
Campbell CT; McCaleb R; Manasco KB
Ann Pharmacother; 2016 Feb; 50(2):133-40. PubMed ID: 26692274
[TBL] [Abstract][Full Text] [Related]
25. Managing Pseudomonas aeruginosa respiratory infections in cystic fibrosis.
Langan KM; Kotsimbos T; Peleg AY
Curr Opin Infect Dis; 2015 Dec; 28(6):547-56. PubMed ID: 26524327
[TBL] [Abstract][Full Text] [Related]
26. Tobramycin inhalation powder (TOBI Podhaler) for the treatment of lung infection in patients with cystic fibrosis.
Vazquez-Espinosa E; Marcos C; Alonso T; Giron RM; Gomez-Punter RM; Garcia-Castillo E; Zamora E; Cisneros C; Garcia J; Valenzuela C; Ancochea J
Expert Rev Anti Infect Ther; 2016; 14(1):9-17. PubMed ID: 26559549
[TBL] [Abstract][Full Text] [Related]
27. The approach to Pseudomonas aeruginosa in cystic fibrosis.
Bendiak GN; Ratjen F
Semin Respir Crit Care Med; 2009 Oct; 30(5):587-95. PubMed ID: 19760546
[TBL] [Abstract][Full Text] [Related]
28. Aerosolized antibiotics in cystic fibrosis: an update.
Fiel SB
Expert Rev Respir Med; 2014 Jun; 8(3):305-14. PubMed ID: 24838090
[TBL] [Abstract][Full Text] [Related]
29. Long-term amikacin liposome inhalation suspension in cystic fibrosis patients with chronic P. aeruginosa infection.
Bilton D; Fajac I; Pressler T; Clancy JP; Sands D; Minic P; Cipolli M; Galeva I; Solé A; Quittner AL; Jumadilova Z; Ciesielska M; Konstan MW;
J Cyst Fibros; 2021 Nov; 20(6):1010-1017. PubMed ID: 34144923
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis.
Stanojevic S; Waters V; Mathew JL; Taylor L; Ratjen F
J Cyst Fibros; 2014 Mar; 13(2):172-8. PubMed ID: 24091166
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of inhaled amikacin as adjunct to intravenous combination therapy (ceftazidime and amikacin) in cystic fibrosis.
Schaad UB; Wedgwood-Krucko J; Suter S; Kraemer R
J Pediatr; 1987 Oct; 111(4):599-605. PubMed ID: 3309236
[TBL] [Abstract][Full Text] [Related]
32. [Efficacy and future of the aerosoltherapy in the treatment of cystic fibrosis patients infected by Pseudomonas aeruginosa].
Rognon A; Curti C; Montana M; Terme T; Rathelot P; Vanelle P
Therapie; 2011; 66(6):481-91. PubMed ID: 22186073
[TBL] [Abstract][Full Text] [Related]
33. Aerosolized antibiotic therapy for chronic cystic fibrosis airway infections: continuous or intermittent?
Lo D; VanDevanter DR; Flume P; Smyth A
Respir Med; 2011 Dec; 105 Suppl 2():S9-17. PubMed ID: 22208548
[TBL] [Abstract][Full Text] [Related]
34. A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients.
Stuart Elborn J; Geller DE; Conrad D; Aaron SD; Smyth AR; Fischer R; Kerem E; Bell SC; Loutit JS; Dudley MN; Morgan EE; VanDevanter DR; Flume PA
J Cyst Fibros; 2015 Jul; 14(4):507-14. PubMed ID: 25592656
[TBL] [Abstract][Full Text] [Related]
35. Pathophysiology and management of pulmonary infections in cystic fibrosis.
Gibson RL; Burns JL; Ramsey BW
Am J Respir Crit Care Med; 2003 Oct; 168(8):918-51. PubMed ID: 14555458
[TBL] [Abstract][Full Text] [Related]
36. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides.
Young DC; Zobell JT; Stockmann C; Waters CD; Ampofo K; Sherwin CM; Spigarelli MG
Pediatr Pulmonol; 2013 Nov; 48(11):1047-61. PubMed ID: 24000183
[TBL] [Abstract][Full Text] [Related]
37. Early antibiotic treatment for Pseudomonas aeruginosa eradication in patients with cystic fibrosis: a randomised multicentre study comparing two different protocols.
Taccetti G; Bianchini E; Cariani L; Buzzetti R; Costantini D; Trevisan F; Zavataro L; Campana S;
Thorax; 2012 Oct; 67(10):853-9. PubMed ID: 22379071
[TBL] [Abstract][Full Text] [Related]
38. [TOBI Podhaler for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis patients].
Pierart F
Rev Med Liege; 2013 Sep; 68(9):486-8. PubMed ID: 24180205
[TBL] [Abstract][Full Text] [Related]
39. Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: a review.
Ratjen F; Brockhaus F; Angyalosi G
J Cyst Fibros; 2009 Dec; 8(6):361-9. PubMed ID: 19747887
[TBL] [Abstract][Full Text] [Related]
40. Inhaled antibiotics in Cystic Fibrosis (CF) and non-CF bronchiectasis.
Tay GT; Reid DW; Bell SC
Semin Respir Crit Care Med; 2015 Apr; 36(2):267-86. PubMed ID: 25826593
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]